<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Further complicating the pandemic is South Africa’s roll-out of a new first-line ARV, a fixed-dose combination pill containing tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD). South Africa has changed to a first line dolutegravir-based regimen because of its higher barrier to resistance and reduction in associated side effects compared to efavirenz. In 2019 the change to TLD was delayed over concerns of increased neural tube defects when women conceive on TLD. However, reassured by improved Botswana data and persuaded that ARV programs must respect a woman’s right to make her own healthcare decisions, the South African National Department of Health launched TLD on December 1, 2019 [
 <xref ref-type="bibr" rid="CR4">4</xref>–
 <xref ref-type="bibr" rid="CR6">6</xref>]. Providers began prescribing TLD nationwide in January 2020.
</p>
